Ilaris (canakinumab) is a type of monoclonal antibody known as an interleukin-1β (IL-1β) blocker. It's taken by adults and children to certain inflammatory conditions, including periodic fever syndromes, Still's disease (a rare type of arthritis), and gout flares. Ilaris (canakinumab) is injected under the skin every 1 to 2 months, depending on your condition, by a healthcare provider. Some of the more common side effects of Ilaris (canakinumab) include higher risk of infection and injection-site reactions.
Ilaris (canakinumab) is a monoclonal antibody. More specifically, it's an interleukin antagonist. It blocks a protein from your immune system, called interleukin-1β (or interleukin-1 beta), to help lower inflammation in the body.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Please note: Side effects listed were reported by people who took Ilaris (canakinumab) for certain types of periodic fever syndromes (TRAPS, HIDS/MKD, and FMF).
Contact your healthcare provider immediately if you experience any of the following.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur:
More common
Body aches or pain
chills
dryness or soreness of the throat
headache
hoarseness
joint pain
loss of appetite
muscle aches and pains
shivering
stomach pain
stuffy or runny nose
sweating
tender, swollen glands in the neck
tightness in the chest
trouble breathing or swallowing
trouble sleeping
unusual tiredness or weakness
voice changes
vomiting
Incidence not known
lightheadedness or dizziness
skin rash, itching
swelling of the face, tongue, and throat
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
feeling of constant movement of self or surroundings
increased weight
muscle or bone pain
sensation of spinning
weakness
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Ilaris (canakinumab) is made by Novartis, a pharmaceutical company.
No, you typically receive Ilaris (canakinumab) injections at your provider's office. But if appropriate, you might be able to arrange for a home health nurse to come to your house and give you the Ilaris (canakinumab) dose at home.
Yes, Ilaris (canakinumab) can be considered an immunosuppressant (a medication that weakens your immune system). This medication blocks a certain protein in your immune system. As a result, it makes the immune system less active.
How long it takes for Ilaris (canakinumab) to work will depend on what condition you're taking it to treat. For example, studies suggest that some people who take Ilaris (canakinumab) for CAPS might expect improvements in their symptoms (e.g., rash, joint pain, headaches) in as early as 1 week. And people who take Ilaris (canakinumab) for SJIA might experience their fever going away after 3 days and improvements in joint pain after about 2 weeks. Keep in mind that everyone responds to Ilaris (canakinumab) differently. So make sure to follow up with your provider about how well Ilaris (canakinumab) is working for your medical condition.
Yes, Ilaris (canakinumab) can cause gain weight. In clinical studies of people taking Ilaris (canakinumab) for CAPS, 11% of people gained weight while receiving treatment. To lower your risk for weight gain while taking Ilaris (canakinumab), make sure to have a healthy diet and regular exercise routine. Talk to your provider if you have more questions about Ilaris (canakinumab) and weight gain.
There isn't enough information to know if Ilaris (canakinumab) is safe to use during pregnancy. Like similar medications, it can pass from mother to baby, especially during the third trimester. As a result, babies born to mothers who took Ilaris (canakinumab) during pregnancy might have weaker immune systems. To lower the risk of getting sick, babies exposed to Ilaris (canakinumab) during pregnancy should avoid live vaccines for at least 4 to 12 months after the mother's last dose. If you're pregnant or thinking of becoming pregnant, speak to your healthcare provider about the risks and benefits of taking Ilaris (canakinumab).
Ask your provider before you receive any vaccines while taking Ilaris (canakinumab). There's limited research about how Ilaris (canakinumab) might affect the way vaccines work. Data shows that this medication isn't likely to affect inactive vaccines. But because Ilaris (canakinumab) weakens your immune system, there's a risk that you can get sick from live vaccines. Examples of live vaccines include the FluMist Quadrivalent (live-attenuated influenza vaccine) nasal spray and MMR (measles, mumps, and rubella vaccine). Check with your provider to make sure you're up-to-date with all vaccines before starting Ilaris (canakinumab).
Ilaris (canakinumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Ilaris (canakinumab) can make it more difficult for your body to fight off infections. This raises your risk of serious bacterial, viral, or fungal infections. The risk is higher for people who are taking or have recently taken other medications that weaken the immune system.
Additionally, Ilaris (canakinumab) might reactivate (wake up) certain viruses that are already in your body, such as tuberculosis (TB) or hepatitis B. Before you start Ilaris (canakinumab) will check to see if you have any current infections.
If you develop an infection, your provider will likely ask you to stop taking Ilaris (canakinumab) until your body fights off the infection. Let your provider know if you experience symptoms of these infections, such as fever, cough, difficulty breathing, or weakness.
Make sure you're up-to-date on routine vaccinations before you start Ilaris (canakinumab). It's unclear how Ilaris (canakinumab) might affect vaccines. But because Ilaris (canakinumab) interferes with your immune system, there's a chance vaccines won't work as well for you. In addition, you're recommended to avoid live vaccines while receiving Ilaris (canakinumab) because there's a risk that you can get sick from the live vaccines. Talk with your provider to see if you still need to schedule any vaccines.
Taking Ilaris (canakinumab) might raise your risk of macrophage activation syndrome (MAS), a serious and life-threatening condition. Let your provider know if you experience symptoms of MAS, such as fever or bleeding that's difficult to stop.
Allergic reactions to Ilaris (canakinumab) are possible. Most common reactions reported were rash at the injection site, a general rash, and hives. But allergic reactions can also include life-threatening reactions like facial swelling, shock, and anaphylaxis (closing of the throat). Get medical attention right away if you notice rash, hives, dizziness, a choking sensation, difficulty breathing, swelling around your eyes, or swelling of the lips or tongue after using Ilaris (canakinumab).
Cryopyrin-associated periodic syndromes (CAPS):
Other types of periodic fever syndromes (TRAPS, HIDS/MKD, and FMF):
AOSD and SJIA:
Gout flares:
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.